changes of high sensitivity c-reactive protein during clopidogrel therapy in patients undergoing percutaneous coronary intervention

conclusions we found that the use of clopidogrel in patients undergoing pci had favorable effects on the suppression of hs-crp. this effect appears to be heightened and more apparent in some group of patients with co-morbidities such as diabetes and hypertension. results six hundred-fifty patients including 386 (59.4%) male and 264 (40.6%) female subjects were enrolled in the study. the mean hs-crp level was 15.36 ± 9.83 mg/l with a median of 14 mg/l (interquartile range 8 to 19.6 mg/l). female, hypertensive, diabetic, and non-smoking patients had higher reductions in hs-crp in response to clopidogrel therapy compared to male, non-hypertensive, non-diabetic and smoker patients, respectively (all p < 0.005). the changes in the hs-crp levels were also statistically different in patients with various index events before pci (p < 0.001). no significant differences were observed in the mean reduction of hs-crp between the patients without stent implantation and those with bare metal or drug-eluting stents (p = 0.07), respectively. background the crucial role of inflammation in the development and progression of atherosclerosis has been previously described. however, there is insufficient data available to demonstrate the changes in high sensitivity c-reactive protein (hs-crp) during clopidogrel therapy. objectives in the present study, we aimed to assess the changes in the inflammatory marker of coronary heart disease, i.e., hs-crp during clopidogrel therapy, in patients undergoing percutaneous coronary intervention (pci). we also evaluated the anti-inflammatory effects of clopidogrel, if any, in different groups of patients. patients and methods the study population included 650 consecutive patients who underwent elective, urgent, or emergent pci. patients received a 300-mg loading dose of clopidogrel (plavix®) and aspirin either 24 hours before the planned pci, or immediately before the procedure in patients with urgent or emergent pci, followed by a 75-mg daily maintenance dose for up to 12 weeks. at the end of the 12th week, hs-crp was re-assessed.